Scoliosis Journals
A person with scoliosis will have a C- or S-shaped curve in their spine. It can appear at any age, but it often presents from the age of 10 to 12 years, or during the teenagers, but infants can sometimes have symptoms. The reasons for the change in shape aren't usually known, but some cases are linked to spastic paralysis, dystrophy, rachischisis, or a congenital anomaly. A structural curve is permanent, and should flow from to a different condition. A nonstructural curve is temporary and it is likely to disappear with time. Scoliosis causes the spine to curve to one side. It can affect any a part of the spine, but the foremost common regions are at the extent of the chest and therefore the lower back. It often appears in children. In most cases, treatment isn't needed, because the curve corrects itself with growth. However, supported the degree of curvature and therefore the age of the kid, a mixture of bracing and
physiotherapy is usually recommended. A very small number of patients with scoliosis may require surgery. Complications of scoliosis include chronic pain, respiratory deficiencies, and decreased exercise capacity. Most children with scoliosis have a light curve that doesn't need treatment. The doctor will recommend following up every 4 to six months to watch the curve of the spine in clinic and periodically with X-rays.
High Impact List of Articles
-
Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal
Giovanni Barosi
Drug Evaluation: Clinical Investigation
-
Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal
Giovanni Barosi
Drug Evaluation: Clinical Investigation
-
Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal
Giovanni Barosi
Drug Evaluation: Clinical Investigation
-
Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal
Giovanni Barosi
Drug Evaluation: Clinical Investigation
-
Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal
Giovanni Barosi
Drug Evaluation: Clinical Investigation
-
Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal
Giovanni Barosi
Drug Evaluation: Clinical Investigation
-
AbobotulinumtoxinA for the treatment of upper limb spasticity
Wolfgang H Jost
Clinical Trail Outcomes: Clinical Investigation
-
AbobotulinumtoxinA for the treatment of upper limb spasticity
Wolfgang H Jost
Clinical Trail Outcomes: Clinical Investigation
-
AbobotulinumtoxinA for the treatment of upper limb spasticity
Wolfgang H Jost
Clinical Trail Outcomes: Clinical Investigation
-
AbobotulinumtoxinA for the treatment of upper limb spasticity
Wolfgang H Jost
Clinical Trail Outcomes: Clinical Investigation
-
AbobotulinumtoxinA for the treatment of upper limb spasticity
Wolfgang H Jost
Clinical Trail Outcomes: Clinical Investigation
-
AbobotulinumtoxinA for the treatment of upper limb spasticity
Wolfgang H Jost
Clinical Trail Outcomes: Clinical Investigation
-
A focus on translational medicine is necessary to close the innovation gap in pharmaceutical medicine
Andreas WallnOfer
Editorial: Clinical Investigation
-
A focus on translational medicine is necessary to close the innovation gap in pharmaceutical medicine
Andreas WallnOfer
Editorial: Clinical Investigation
-
A focus on translational medicine is necessary to close the innovation gap in pharmaceutical medicine
Andreas WallnOfer
Editorial: Clinical Investigation
-
A focus on translational medicine is necessary to close the innovation gap in pharmaceutical medicine
Andreas WallnOfer
Editorial: Clinical Investigation
-
A focus on translational medicine is necessary to close the innovation gap in pharmaceutical medicine
Andreas WallnOfer
Editorial: Clinical Investigation
-
A focus on translational medicine is necessary to close the innovation gap in pharmaceutical medicine
Andreas WallnOfer
Editorial: Clinical Investigation
-
Clinical evidence of the role of edoxaban in anticoagulation
Elena Fortuny ,Jose Zamorano
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical evidence of the role of edoxaban in anticoagulation
Elena Fortuny ,Jose Zamorano
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical evidence of the role of edoxaban in anticoagulation
Elena Fortuny ,Jose Zamorano
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical evidence of the role of edoxaban in anticoagulation
Elena Fortuny ,Jose Zamorano
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical evidence of the role of edoxaban in anticoagulation
Elena Fortuny ,Jose Zamorano
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical evidence of the role of edoxaban in anticoagulation
Elena Fortuny ,Jose Zamorano
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical research in Latin America: obstacles and opportunities
Emmanuel Coronel, Donald Halstead, Felipe Fregni
Editorial: Clinical Investigation
-
Clinical research in Latin America: obstacles and opportunities
Emmanuel Coronel, Donald Halstead, Felipe Fregni
Editorial: Clinical Investigation
-
Clinical research in Latin America: obstacles and opportunities
Emmanuel Coronel, Donald Halstead, Felipe Fregni
Editorial: Clinical Investigation
-
Clinical research in Latin America: obstacles and opportunities
Emmanuel Coronel, Donald Halstead, Felipe Fregni
Editorial: Clinical Investigation
-
Clinical research in Latin America: obstacles and opportunities
Emmanuel Coronel, Donald Halstead, Felipe Fregni
Editorial: Clinical Investigation
-
Clinical research in Latin America: obstacles and opportunities
Emmanuel Coronel, Donald Halstead, Felipe Fregni
Editorial: Clinical Investigation
-
Novel treatment strategies for patients with nonalcoholic fatty liver disease
Brian Lam,Zobair M Younossi
Therapeutic Prospective: Clinical Investigation
-
Novel treatment strategies for patients with nonalcoholic fatty liver disease
Brian Lam,Zobair M Younossi
Therapeutic Prospective: Clinical Investigation
-
Novel treatment strategies for patients with nonalcoholic fatty liver disease
Brian Lam,Zobair M Younossi
Therapeutic Prospective: Clinical Investigation
-
Novel treatment strategies for patients with nonalcoholic fatty liver disease
Brian Lam,Zobair M Younossi
Therapeutic Prospective: Clinical Investigation
-
Novel treatment strategies for patients with nonalcoholic fatty liver disease
Brian Lam,Zobair M Younossi
Therapeutic Prospective: Clinical Investigation
-
Novel treatment strategies for patients with nonalcoholic fatty liver disease
Brian Lam,Zobair M Younossi
Therapeutic Prospective: Clinical Investigation
Relevant Topics in Clinical